Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 22, Issue 5, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2015.12.025
Keywords
Regulatory T-cells; HIV; maraviroc; CCR5; naive-Treg; effector-Treg; non-Treg; homeostasis
Categories
Funding
- Fondo de Investigacion Sanitaria (FIS) [P11/02014]
- Spanish AIDS Research Network of Excellence [RD12/0017/0029, RD12/0017/0037]
- Ministerio de Sanidad, Politica Social e Igualdad [EC11-520]
- Fundacion Progreso y Salud [PI-0081-2011]
- Pfizer/ViiV Healthcare [WS843473, WS2425049]
- Fondo de Investigacion Sanitaria through the Miguel Servet programs [CP07/00240, CPII13/00037]
- Consejeria de Salud y Bienestar Social of Junta de Andalucia through the 'Nicolas Monardes' programme [C-0010/13]
- Fondo de Investigacion Sanitaria through the 'Miguel Servet' programme [CP08/0172]
- Ministry of Economy and Competitiveness (Ramon y Cajal grant) [RYC-2010-07419]
Ask authors/readers for more resources
Regulatory T (Treg) cells comprise different functional subsets with different CCR5 expression. Treg homeostasis is disrupted by HIV but the effect of treatment has barely been explored. In a longitudinal design, we compared the effect of a maraviroc-containing (n = 9) or sparing (n = 12) therapy in antiretroviralnaive HIV-positive participants on peripheral FoxP3(low) CD45RA(+) (nTreg), FoxP3(high) CD45RA(-) (eTreg) and FoxP3(low) CD45RA(-) (non-Treg) cells. Maraviroc significantly reduced all subsets in the short-term and, except for nTreg cells, also normalized them in the long-term. The correlation between eTreg cells and CD4 counts, lost before treatment, was only restored by maraviroc. The differential effect of maraviroc on Treg subsets contributes to understanding its immunomodulatory effects. (C) 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available